“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced its plans to explore utilizing Molecular Envelope Technology (MET) ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

"Our proprietary T&T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal Naloxone by offering higher bioavailability for increased drug ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target cancer cells.

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

Global Nanotechnology Drug Delivery Market is valued at USD 85.5 Billion in 2022. Global Nanotechnology Drug Delivery Market ...

Intranasal (IN) delivery of medications is a relatively new area of interest in the field of transmucosal medication delivery, but is gaining popularity in the world of healthcare for several reasons.

In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision ...